The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial
Clin Nutr, . 2020 Nov 7;S0261-5614(20)30609-9. doi: 10.1016/j.clnu.2020.11.005
Abolfazl Zendehdel 1, Mohsen Ansari 2, Farnaz Khatami 3, Shapour Mansoursamaei 4, Hossein Dialameh 5
Items in both categories Cancer - Prostate and Intervention are listed here:
- BPH (PSA) decreased by Vitamin D (50,000 IU bi-weekly) – RCT Nov 2020
- Prostate Cancer might be treated by 4,000 IU of vitamin D and aspirin – RCT 2021
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
- Prostate cancer reduced when 4000 IU vitamin D was added– Hollis RCT April 2015
- Low risk Prostate Cancer decreased with 4,000 IU of vitamin D – July 2012
Meta-analyses of Prostate Cancer
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Variety of Vitamin D forms treat Prostate Cancer – RCT Review April 2019
- Prostate Cancer death 40 percent less likely if 40 ng level of vitamin D – Meta-analysis Oct 2018
- Prostate cancer risk increase with Vitamin D (other studies disagree) – meta-analysis Jan 2018
- Meta-graphs of vitamin D and Cancer – Dec 2011
- Risk of Prostate Cancer weakly associated with vitamin D - meta-analysis March 2011
- 16 percent less Prostate Cancer sometimes for each 10 ng vitamin D increase - meta-analysis Jan 2011
- Meta-analysis found vitamin D association with colon but not prostate nor breast cancer May 2010
Background and aims: Inflammation and proliferation are the cause of benign prostatic hyperplasia (BPH) and are the key components of its mechanism of action. In this study we sought to determine the role of 25-hydroxyvitamin D in BPH, because of its anti-inflammatory activities, and its effect on prostate volume and BPH symptoms.
Methods: This randomized clinical trial (RCT) was conducted on 108 participants >50 years of age who had either asymptomatic or mild BPH symptoms according to the International Prostate Symptom Score (IPSS) questionnaire. Patients were randomly divided into two groups, intervention and control. The intervention group received 50 000 units of vitamin D3 and the control group received a placebo every two weeks for six months. Prostate ultrasound, routine clinical examinations, toucher rectal (TR), and laboratory tests were performed for all patients. After six months, the patients underwent another ultrasound evaluation, measurement of prostate-specific antigen (PSA) levels and completed the IPSS. Results of the evaluations before and after the intervention were compared between the groups using the chi-square, t-test, and logistic regression analysis. Repeated measure analysis was used to evaluate the effect of vitamin D intervention on the changes in the IPSS score.
Results: The mean age of the participants was 56 ± 9 years. In the control group, the mean prostate volume was higher compared to the intervention group (p < 0.001). The control group had a higher mean PSA level than the intervention group (p < 0.001). Although the IPSS score decreased over time in both groups, analysis of variance showed that the amount of change or decrease in IPSS score in the intervention group was significantly more than the control group (p < 0.001).
Conclusions: The results of our study support the effect of vitamin D in reducing prostate volume and PSA levels, and in improving BPH symptoms. Further studies are needed to confirm these findings to verify the use of vitamin D as a treatment for BPH.
|85 visitors, last modified 21 Nov, 2020,